CENTRAL NERVOUS SYSTEM TUMORS
Primary central nervous system (CNS) tumors are a group of tumor types originating from the brain or spinal cord tissue, and can be differentiated from metastatic brain tumors that spread to the brain from a tumor developed in another part of the body. Although certain genetic syndromes may increase the risk of developing CNS tumors, the causes of most adult primary CNS tumors are still unknown.
CNS tumors can be benign or malignant. Current standard treatment options consist of surgery, radiation therapy and chemotherapy. Recent genome-wide studies of malignant CNS tumors have unveiled molecular biomarkers that may influence clinical treatment decision-making – some of which have been incorporated by the World Health Organization (WHO) into Classification of Tumors of the Central Nervous System in 2016. These tumors were classified based on both histological appearance and molecular parameters.
NEUROCAN™
Targets 106 key genes in central nervous system tumors
- Facilitates CNS tumor classification and grading
- Utilizes associated genetic biomarkers to predict efficacy and toxicity of chemotherapy
- Assesses genetic predisposition to CNS tumors
- Optional MGMT promoter methylation test
WHO IS IT FOR
- Patients with central nervous system tumors seeking precision medicine
- Individual with family history of familial CNS tumor syndromes
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
GLIOCAN™
Targets 12 key molecular biomarkers in glioma
- Comprehensive testing of genetic alterations such as diagnostic, prognostic or predictive biomarkers in glioma, including 1p/19q co-deletion, mutations in ATRX, BRAF, IDH1, IDH2, TERT and TP53 genes
- Facilitates tumor classification and grading
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Optional MGMT promoter methylation test
WHO IS IT FOR
- Newly diagnosed glioma patients seeking precision medicine
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
NEUROPRO™
Targets 494 key genes in central nervous system tumors
- Detection of single nucleotide variants (SNVs), small insertions and deletions (indels), gene fusions, copy number variations (CNVs), chromosomal aberration, and O(6)- methylguanine-DNA methyltransferase (MGMT) promoter methylation to characterize central nervous system (CNS) tumor subtypes and guide personalized treatment
- Comprehensive evaluation of genes recommended in WHO/NCCN/CSCO guidelines to reveal clinical benefits
- Assess targetable gene alterations to match patients for targeted therapy and immunotherapy
- Hereditary cancer risk assessment for early intervention
- Coverage of prognosis-related genes to direct treatment decision making
WHO IS IT FOR
- Newly diagnosed patients
- Patients with an unclear CNS diagnosis
- Patients seeking personalized treatment plans
- Patients that experience ineffective conventional treatments
SAMPLE TYPES*
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
*MGMT and 1p/19q detection only apply to tumor tissue samples
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.